Total cholesterol and LDL cholesterol were reduced in all trials but there was evidence of heterogeneity of effects .
There was no evidence of any serious harm caused by statin prescription .
Evidence available to date showed that primary prevention with statins is likely to be cost-effective and may improve patient quality of life .
Recent findings from the Cholesterol Treatment Trialists study using individual patient data meta- analysis indicate that these benefits are similar in people at lower ( < 1 % per year ) risk of a major cardiovascular event .
AUTHORS ' CONCLUSIONS Reductions in all-cause mortality , major vascular events and revascularisations were found with no excess of adverse events among people without evidence of CVD treated with statins
BACKGROUND Reducing high blood cholesterol , a risk factor for cardiovascular disease ( CVD ) events in people with and without a past history of CVD is an important goal of pharmacotherapy .
Statins are the first-choice agents .
Previous review s of the effects of statins have highlighted their benefits in people with CVD .
The case for primary prevention was uncertain when the last version of this review was published ( 2011 ) and in light of new data an up date of this review is required .
OBJECTIVES To assess the effects , both harms and benefits , of statins in people with no history of CVD .
Fluvastatin Prevents Cardiac Death and Myocardial Infarction in Renal Transplant Recipients: Post‐Hoc Subgroup Analyses of the ALERT Study
Renal transplant recipients have a greatly increased risk of  premature cardiovascular disease . The ALERT study was a multicenter , r and omized , double‐blind , placebo‐controlled trial of fluvastatin ( 40–80 mg/day ) in 2102 renal transplant recipients followed for 5–6 years . The main study used a composite cardiac end‐point including myocardial infa rct ion , cardiac death and cardiac interventions . Although reduced by fluvastatin , this primary end‐point failed to achieve statistical significance thus precluding analysis of predefined subgroups . Therefore , in the present survival analysis , we used an alternative primary end‐point of cardiac death or definite nonfatal myocardial infa rct ion ( as used in other cardiac outcome trials ) which was significantly reduced by Fluvastatin therapy and permits subgroup analysis . Fluvastatin  reduced LDL‐cholesterol by 1 mmol/L compared with placebo , and the incidence of cardiac death or definite myocardial infa rct ion was reduced from 104 to 70 events ( RR 0.65 ; 95 % CI 0.48 , 0.88 ; p = 0.005 ) . Fluvastatin use was associated with reduction in cardiac death or nonfatal myocardial infa rct ion , which achieved statistical significance in many subgroups . The subgroups included patients at lower cardiovascular risk , who were younger , nondiabetic , nonsmokers and without pre‐existing CVD . These data support the early introduction of statins following renal transplantation
Total cholesterol and LDL cholesterol were reduced in all trials but there was evidence of heterogeneity of effects .
There was no evidence of any serious harm caused by statin prescription .
Evidence available to date showed that primary prevention with statins is likely to be cost-effective and may improve patient quality of life .
Recent findings from the Cholesterol Treatment Trialists study using individual patient data meta- analysis indicate that these benefits are similar in people at lower ( < 1 % per year ) risk of a major cardiovascular event .
AUTHORS ' CONCLUSIONS Reductions in all-cause mortality , major vascular events and revascularisations were found with no excess of adverse events among people without evidence of CVD treated with statins
BACKGROUND Reducing high blood cholesterol , a risk factor for cardiovascular disease ( CVD ) events in people with and without a past history of CVD is an important goal of pharmacotherapy .
Statins are the first-choice agents .
Previous review s of the effects of statins have highlighted their benefits in people with CVD .
The case for primary prevention was uncertain when the last version of this review was published ( 2011 ) and in light of new data an up date of this review is required .
OBJECTIVES To assess the effects , both harms and benefits , of statins in people with no history of CVD .